Structure-based Ligand Design and the Promise Held for Antiprotozoan Drug Discovery*

The development of the pharmaceutical industry, driven by progress in chemistry, biology, and technology, ranks as one of the most successful of human endeavors. However, serious health problems persist, among which are diseases caused by protozoan parasites, largely ignored in modern times. Advances in genomic sciences, molecular and structural biology, and computational and medicinal chemistry now set the scene for a renewed assault on such infections. A structure-centric approach to support discovery of antiparasitic compounds promises much. Current strategies and benefits of a structure-based approach to support early stage drug discovery will be described.

[1]  M. Barrett,et al.  Human African trypanosomiasis: pharmacological re‐engagement with a neglected disease , 2007, British journal of pharmacology.

[2]  A. Fairlamb,et al.  Drug Resistance in Leishmaniasis , 2006, Clinical Microbiology Reviews.

[3]  P. Myler,et al.  Searching the Tritryp Genomes for Drug Targets , 2008, Advances in experimental medicine and biology.

[4]  G. Superti-Furga,et al.  Rediscovering the sweet spot in drug discovery. , 2003, Drug discovery today.

[5]  Kate E. Jones,et al.  Global trends in emerging infectious diseases , 2008, Nature.

[6]  T. Keller,et al.  A practical view of 'druggability'. , 2006, Current opinion in chemical biology.

[7]  N. Sahu,et al.  Novel Molecular Targets for Antimalarial Drug Development , 2008, Chemical biology & drug design.

[8]  Daniel R. Caffrey,et al.  Structure-based maximal affinity model predicts small-molecule druggability , 2007, Nature Biotechnology.

[9]  Gloria Rudenko,et al.  Switching trypanosome coats: what's in the wardrobe? , 2006, Trends in genetics : TIG.

[10]  J. G. Robertson,et al.  Mechanistic basis of enzyme-targeted drugs. , 2005, Biochemistry.

[11]  Tom L. Blundell,et al.  Keynote review: Structural biology and drug discovery , 2005 .

[12]  Adam R Renslo,et al.  Drug discovery and development for neglected parasitic diseases , 2006, Nature chemical biology.

[13]  Michael P Barrett,et al.  Chemotherapy of trypanosomiases and leishmaniasis. , 2005, Trends in parasitology.

[14]  Joseph D. Smith,et al.  Antigenic Variation in Plasmodium falciparum: Gene Organization and Regulation of the var Multigene Family , 2007, Eukaryotic Cell.

[15]  John C Dearden,et al.  In silico prediction of ADMET properties: how far have we come? , 2007, Expert opinion on drug metabolism & toxicology.

[16]  T. O'Brien,et al.  Fragment-based drug discovery. , 2004, Journal of medicinal chemistry.

[17]  Brian K. Shoichet,et al.  Virtual screening of chemical libraries , 2004, Nature.

[18]  Solomon Nwaka,et al.  Innovative lead discovery strategies for tropical diseases , 2006, Nature Reviews Drug Discovery.

[19]  M. Congreve,et al.  Fragment-based lead discovery , 2004, Nature Reviews Drug Discovery.

[20]  P. Bork,et al.  Drug Target Identification Using Side-Effect Similarity , 2008, Science.

[21]  G. McFadden,et al.  Fatty acid synthesis in protozoan parasites: unusual pathways and novel drug targets. , 2008, Current pharmaceutical design.

[22]  Andrew J Tatem,et al.  The global distribution and population at risk of malaria: past, present, and future. , 2004, The Lancet. Infectious diseases.

[23]  R. Altman,et al.  Drug Targets for Plasmodium falciparum: a post-genomic review/survey. , 2006, Mini reviews in medicinal chemistry.

[24]  R. Krauth-Siegel,et al.  The Parasite-Specific Trypanothione Metabolism of Trypanosoma and Leishmania , 2003, Biological chemistry.

[25]  David J Newman,et al.  Natural products as leads to potential drugs: an old process or the new hope for drug discovery? , 2008, Journal of medicinal chemistry.

[26]  F. Lombardo,et al.  Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings , 1997 .

[27]  A. Hopkins,et al.  The druggable genome , 2002, Nature Reviews Drug Discovery.

[28]  C. Naula,et al.  Protein kinases as drug targets in trypanosomes and Leishmania. , 2005, Biochimica et biophysica acta.

[29]  A. Hopkins,et al.  Ligand efficiency: a useful metric for lead selection. , 2004, Drug discovery today.

[30]  E. Espeso,et al.  Carbon catabolite repression can account for the temporal pattern of expression of a penicillin biosynthetic gene in Aspergillus nidulans , 1992, Molecular microbiology.

[31]  P. Hajduk,et al.  A decade of fragment-based drug design: strategic advances and lessons learned , 2007, Nature Reviews Drug Discovery.

[32]  Daniel James,et al.  Lessons Learnt from Assembling Screening Libraries for Drug Discovery for Neglected Diseases , 2007, ChemMedChem.

[33]  William N. Hunter,et al.  The Non-mevalonate Pathway of Isoprenoid Precursor Biosynthesis* , 2007, Journal of Biological Chemistry.

[34]  John P. Overington,et al.  Can we rationally design promiscuous drugs? , 2006, Current opinion in structural biology.

[35]  A. Hopkins,et al.  Navigating chemical space for biology and medicine , 2004, Nature.

[36]  David S Roos,et al.  Protozoan genomics for drug discovery , 2005, Nature Biotechnology.

[37]  Simon Croft,et al.  Kinetoplastids: related protozoan pathogens, different diseases. , 2008, The Journal of clinical investigation.

[38]  I. Gilbert,et al.  Target assessment for antiparasitic drug discovery. , 2007, Trends in parasitology.

[39]  Herbert Waldmann,et al.  Therapeutic intervention based on protein prenylation and associated modifications , 2006, Nature chemical biology.

[40]  A. Hopkins.  Network pharmacology: the next paradigm in drug discovery. , 2008, Nature chemical biology.

[41]  D. Newman,et al.  Natural products as sources of new drugs over the last 25 years. , 2007, Journal of natural products.